Dr. Wessel: Axxima Pharmaceuticals AG is a drug discovery and development company, pioneering the novel strategy of generating a “Signal Transduction Firewall” against infections, related diseases and disorders, such as inflammation. By blocking critical signal transduction pathways required by pathogens for their survival, Axxima´s compounds target entirely novel mechanisms for combating resistance formation. Our company, founded by Dr. Axel Ullrich, started with the first financing round in 1998. With 3 private financing rounds, Axxima has raised a total of €54 million and has established a solid drug development infrastructure. The most advanced projects currently include HIV, Hepatitis C, tuberculosis and HCMV.
TWST: Can you elaborate on a kind of solutions that you are going to bring to the market?
Dr. Wessel: Axxima´s compounds address entirely novel mechanisms for fighting resistance formation. The new generation of drugs, with a high selectivity developed by Axxima, will prevent the pathogen from hijacking the communication system of the cell for their own purposes, addressing the market's urgent need for novel approaches in infectious diseases. Tapping its pipeline, Axxima plans to out-license, sell or partner products at defined development stages to customers in the pharmaceutical industry. Typical products are compounds in pre-clinical or clinical development, optimized lead compounds or selected validated targets. Additionally, Axxima plans to partner its drug discovery technology in indications outside of Axxima´s core focus areas.
For more information call (212) 952 7433. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.